WEKO3
アイテム
{"_buckets": {"deposit": "5c6e0525-f9f4-46dc-a78b-18fe524ce54a"}, "_deposit": {"created_by": 1, "id": "45406", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "45406"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00045406", "sets": ["1"]}, "author_link": ["451040", "451036", "451038", "451039", "451037"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2008-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "8", "bibliographicPageEnd": "1195", "bibliographicPageStart": "1183", "bibliographicVolumeNumber": "32", "bibliographic_titles": [{"bibliographic_title": "Leukemia Research"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Microsatellite instability (MSI) in haematopoietic malignancies has been controversial. Particularly in non-Hodgkin lymphoma, the data published to date lack unity. Using a unique fluorescent technique, we found MSI in eight (14%) tumours in a panel of 59 carefully selected non-Hodgkin lymphoma patients. Our fluorescent technique also reveals two qualitatively distinct modes of MSI, i.e. Type A and Type B. Based on our previous studies using DNA mismatch repair (MMR) gene-knock out animals, we have concluded that Type A MSI is a direct consequence of defective MMR. MSI observed in non-Hodgkin lymphomas was uniformly Type A, which implies that MMR deficiency occurs in this malignancy. Intriguingly, in non-Hodgkin lymphoma patients treated by CHOP/VEPA-based therapies, response to chemotherapy was significantly worse in those with microsatellite-unstable tumours (p = 0.027). As a consequence, the patient outcomes at 1 year after treatment were significantly less favourable in this population (p = 0.046), although the survival difference was not statistically confirmed in a longer term. These findings suggest that in some non-Hodgkin lymphomas MMR deficiency may lead to drug resistance in tumour cells and, consequently, to poor patient outcomes. In non-Hodgkin lymphoma, MSI may be a potential biomarker that predicts the tumour response against chemotherapy.", "subitem_description_type": "Abstract"}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0145-2126", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Miyashita, Kaname"}], "nameIdentifiers": [{"nameIdentifier": "451036", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida, Mitsuaki"}], "nameIdentifiers": [{"nameIdentifier": "451037", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oda, Shinya"}], "nameIdentifiers": [{"nameIdentifier": "451038", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "et.al"}], "nameIdentifiers": [{"nameIdentifier": "451039", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉田 光明", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "451040", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/45406", "pubdate": {"attribute_name": "公開日", "attribute_value": "2009-01-28"}, "publish_date": "2009-01-28", "publish_status": "0", "recid": "45406", "relation": {}, "relation_version_is_last": true, "title": ["Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy"], "weko_shared_id": -1}
Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy
https://repo.qst.go.jp/records/45406
https://repo.qst.go.jp/records/454068f6c8605-fcf3-4499-8108-d00390fcc8a7
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2009-01-28 | |||||
タイトル | ||||||
タイトル | Frequent microsatellite instability in non-Hodgkin lymphomas irresponsive to chemotherapy | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Miyashita, Kaname
× Miyashita, Kaname× Yoshida, Mitsuaki× Oda, Shinya× et.al× 吉田 光明 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Microsatellite instability (MSI) in haematopoietic malignancies has been controversial. Particularly in non-Hodgkin lymphoma, the data published to date lack unity. Using a unique fluorescent technique, we found MSI in eight (14%) tumours in a panel of 59 carefully selected non-Hodgkin lymphoma patients. Our fluorescent technique also reveals two qualitatively distinct modes of MSI, i.e. Type A and Type B. Based on our previous studies using DNA mismatch repair (MMR) gene-knock out animals, we have concluded that Type A MSI is a direct consequence of defective MMR. MSI observed in non-Hodgkin lymphomas was uniformly Type A, which implies that MMR deficiency occurs in this malignancy. Intriguingly, in non-Hodgkin lymphoma patients treated by CHOP/VEPA-based therapies, response to chemotherapy was significantly worse in those with microsatellite-unstable tumours (p = 0.027). As a consequence, the patient outcomes at 1 year after treatment were significantly less favourable in this population (p = 0.046), although the survival difference was not statistically confirmed in a longer term. These findings suggest that in some non-Hodgkin lymphomas MMR deficiency may lead to drug resistance in tumour cells and, consequently, to poor patient outcomes. In non-Hodgkin lymphoma, MSI may be a potential biomarker that predicts the tumour response against chemotherapy. | |||||
書誌情報 |
Leukemia Research 巻 32, 号 8, p. 1183-1195, 発行日 2008-08 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0145-2126 |